Olanzapine open-label studies

Kumra S., Jacobsen, L.K., Lenane, M., Karp, B.I., Frazier, J.A., Smith, A.K., Bedwell, J., Lee, R, Malanga, C.J., Hamburger, S., and Rapoport, J.L. (1998) Childhood-onset schizophrenia an open-label study of olanzapine in adolescents. / Am Acad Child Adolesc Psychiatry 37 377-385. 

Budman, C.L., Gayer, A., Lesser, M., Shi, Q., and Bruun, R.D. (2001) An open-label study of the treatment efficacy of olanzapine for Tourette s disorder. / Clin Psychiatry 62 290—294. 

Kumar S, Jacobson LK, Lenane M, et al. Childhood onset schizophrenia an open label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry 1998 37 377-385. 

Gimenez-Roldan S, Mateo D, Navarro E, Gines MM. Efficacy and safety of clozapine and olanzapine an open-label study comparing two groups of Parkinson s disease patients with dopaminergic-induced psychosis. Parkinsonism Relat Disord 2001 7(2) 121-7. 

Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G. Olanzapine as a possible treatment of behavioral symptoms in vascular dementia risks of cerebrovascular events. A controlled, open-label study. J Neurol 2005 252 1186-93. 

Results of low-dose risperidone (0.5 to 2 mg/day) added to antidepressant therapy in refractory patients are encouraging. Treatment response over 6 weeks was rapid and consistent. An additional 8-week, open-label study reported that 50% of patients previously unresponsive to clomipramine responded after risperidone 3 mg/day was added. The recommended initial dose of risperidone is 0.25 mg, and the target dose is 0.5 to 5 mg/day. Thirty-six patients unresponsive to antidepressants were given risperidone, up to 6 mg/day or placebo in a double-blind trial. Risperidone treatment resulted in a significant reduction in YBOCS scores. " In an open-label trial of olanzapine augmentation of SSRIs for 8 weeks, most patients experienced complete or partial remission in doses of 1.25 to 20 mg/day. ... 

Other atypical antipsychotics commonly prescribed for treatment of autism include olanzapine, quetiapine, ziprasidone, and clozapine (Oswald and Sonenklar, 2007). Placebo-controlled trials of these agents in ASD populations have not been reported, with the exception of a small pilot study of olanzapine in which three of six children treated with olanzepine were rated as responders, compared to one of five in the placebo group (Hollander et al., 2006b). Open-label studies (reviewed by... 

In an open-label study, 12 healthy subjects took a single 32.4-mmol dose of lithium with olanzapine 10 mg, and after a washout period, olanzapine 10 mg daily for 8 days, with a single 32.4-mmol dose of lithium on the last day. No pharmaeokinetic interactions were detected. However, an analysis of olanzapine levels in schizophrenic patients found that concurrent lithium was associated with lower olanzapine plasma levels. ... 

Dittmann RW, Meyer E, Freisleder FJ, Remschmidt H, Mehler-Wex C, Junghanss J, Hagenah U, Schulte-Markwort M, Poustka F, Schmidt MH, Schulz E, Mastele A, Wehmeier PM. Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders results from a large, prospective, open-label study. J Child Adolesc Psychopharmacol 2008 18(1) 54-69. 

Potenza, M.N., Holmes, J.P., Kanes, S.J., and McDougle, C.J. (1999) Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders an open-label pilot study. J Clin Psychopharmacol 19 37—44. 

Marangeh LB, Johnson CR, Kertz B, et al Olanzapine in the treatment of apathy in previously depressed participants maintained on SSRIs an open label, flexible-dose study. J Clin Psychiatry 63 391-395, 2002... 

Namjoshi and coworkers (297) reported the results of an extension phase study comparing olanzapine with placebo. The initial reduction achieved in YMS scores continued during this period and by the end of the extension phase reached a mean reduction of 18-points. The authors also conducted an economic analysis of the drug trial (excluding the acute treatment period) and found that the cost per month seen in the open-label extension phase (i.e., 649) was about half of that observed during the 12 months before entering the study (i.e., 1,533.)... 

Stewart RS, Nejtek VA. An open-label, flexible-dose study of olanzapine in the treatment of trichotillomania. J Clin Psychiatry 2003 64 49-52. 

Choure BK, Gosavi D, Nanotkar S (2014) Comparative cardiovascular safety of risperidone and olanzapine, based on electrocardiographic parameters and blood pressure a prospective open label observational study. Indian J Pharmacol 46 493 97... 

Kumra S, Kranzier H, Gerbino-Rosen G, Kester HM, DeThomas C, Cullen K, Regan J, Kane JM. Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia an open-label extension study. J Child Adolesc Psychopharmacol 2008 18(4) 307-16. 

Ganguli R, Brar JS, Mahmoud R, Berry SA, Pandina GJ. Assessment of strategies for switching patients from olanzapine to risperidone a randomized, open-label, rater-blinded study. BMC Med 2008 6 17. 

---